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Pemphigus foliaceus (PF) is a human autoimmune
blistering disease in which a humoral immune re-
sponse targeting the skin results in a loss of keratin-
ocyte cell-cell adhesion in the superficial layers of the
epidermal epithelium. In PF, desmoglein-1-specific
autoantibodies induce blistering. Evidence is begin-
ning to accumulate that activation of signaling may
have an important role in the ability of pathogenic
pemphigus IgGs to induce blistering and that both
p38 mitogen-activated protein kinase (MAPK) and
heat shock protein (HSP) 27 are part of this signaling
pathway. This study was undertaken to investigate the
ability of PF IgGs to activate signaling as well as the
contribution of this signaling pathway to blister induction
in an in vivo model of PF. Phosphorylation of both p38
MAPK and HSP25, the murine HSP27 homolog, was ob-
served in the skin of PF IgG-treated mice. Furthermore,
inhibition of p38 MAPK blocked the ability of PF IgGs to
induce blistering in vivo. These results indicate that PF
IgG-induced blistering is dependent on activation of p38
MAPK in the target keratinocyte. Rather than influencing
the immune system, limiting the autoantibody-induced
intracellular signaling response that leads to target end-
organ damage may be a more viable therapeutic strategy
for the treatment of autoimmune diseases. Inhibi-
tion of p38 MAPK may be an effective strategy for
the treatment of PF. (Am J Pathol 2008, 173:1628–1636;
DOI: 10.2353/ajpath.2008.080391)
The treatment of immunobullous disorders, in which an
autoimmune response targets the skin to cause loss of
epidermal integrity, has traditionally used agents that
suppress the immune response. With a compromised
epithelial barrier, patients are at risk for fluid and electro-
lyte imbalance and infection. Untreated, these disorders
can be lethal. The introduction of corticosteroids revolu-
tionized the treatment of autoimmune skin disease; how-
ever, chronic use of systemic corticosteroids carries
significant morbidity and mortality. Steroid-sparing
agents and therapies that target specific components
of the immune response have been used to minimize
these complications; however, immune suppression it-
self carries risk, including the potential for infectious
complications. Rather than inhibit the immune system,
an alternative strategy would be to block the ability of
the autoimmune response to damage the target end-
organ.
The pemphigus family of human autoimmune blistering
diseases offers several advantages in the study of auto-
immunity and the development of specific mechanism
based therapies: i) end-organ damage is readily visible as
a blister, ii) the pathogenic target autoantigens are de-
fined,1–3 iii) in vivo models are available,4–6 and iv) the skin
is accessible to topical as well as systemically delivered
drugs. In pemphigus, a humoral immune response targets
epithelial structures leading to loss of cell-cell adhesion and
blister formation. The two major variants are pemphigus
foliaceus (PF) and pemphigus vulgaris (PV).
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Desmogleins, transmembrane nonclassical cadherin
cell adhesion proteins, are the major pathogenic autoan-
tibody targets of both pemphigus variants. Clinically, PV
is characterized by flaccid vesicles and erosions of mu-
cosa (mucosal PV) and subsequently mucosa and skin
(mucocutaneous PV), whereas PF is characterized by
superficial crusted vesicles and blisters. Histologically,
loss of cell-cell adhesion (eg, acantholysis) occurs in the
suprabasal epidermis in PV and in the subcorneal epi-
dermis in PF. In PF, the autoantibody response is di-
rected against desmoglein-1 (dsg1)2 and found in supra-
basilar desmosomes of epidermal epithelia, whereas in
PV, the autoantibody response is initially directed against
desmoglein-3 (dsg3)1,3,7 and found in desmosomes of
the basal layer of stratified epidermal epithelia and in
mucosal epithelia. In PV, the autoantibody response sub-
sequently evolves to include dsg1 as the disease transi-
tions from mucosal to mucocutaneous PV.8–10 Dsg1 and
dsg3 are similar in that they both are transmembrane
proteins of the cadherin superfamily and are components
of desmosome cell-cell adhesion junctions.11 The com-
pensation hypothesis, the ability of dsg1 to compensate
for loss of dsg3 function with the different distribution of
dsg1 and dsg3 in epidermal epithelia and mucosa, has
been proposed to explain the tissue distribution and lo-
cation of the cleavage plane in PV and PF.12
Different mechanisms have been proposed to explain
blister induction by Ig in autoimmune blistering diseases
of the skin. For example, in the human subepidermal
blistering disease bullous pemphigoid (BP), IgGs bind to
the hemidesmosome-associated protein BP180 and trig-
ger a complement-, mast cell-, and neutrophil-dependent
inflammatory cascade culminating in human neutrophil
elastase-dependent proteolytic cleavage of BP180 and
separation at the dermal-epidermal junction.13–18 In con-
trast, pemphigus antibody binding to dsg does not re-
quire inflammatory components to mediate blister forma-
tion; pemphigus IgG induced epidermal cell detachment
is neither Fc-,19 complement-,20 nor proteinase-depen-
dent.21 Steric hindrance, the direct blocking of desmo-
some cadherin-adhesive interactions by pemphigus IgG,
has also been suggested as a mechanism for the adhe-
sive disrupting ability of these immunoglobulins22; how-
ever, steric hindrance alone may not be sufficient to
explain the pathogenic effects because energy-requiring
cellular events are required for pemphigus IgG to induce
acantholysis.23,24
Binding of pemphigus IgG to the keratinocyte has
been proposed to activate intracellular signaling within
the target keratinocyte, and this may contribute to the
loss of cell-cell adhesion.25 In our previous work on PV,
we identified a series of intracellular phosphorylation
events initiated by binding of PV IgG to keratinocytes.
Incubation of cultured human keratinocytes with IgG pu-
rified from PV patient sera resulted in activation of p38
mitogen-activated protein kinase (MAPK), phosphoryla-
tion of the small heat shock protein (HSP) 27, reorgani-
zation of the actin cytoskeleton, and intermediate filament
collapse. In tissue culture, inhibitors of p38MAPK pre-
vented PV IgG-induced phosphorylation of HSP27 and
reorganization of the cytoskeleton, events preceding the
loss of cell-cell adhesion induced by PV IgG.26 These
observations in tissue culture suggested that p38MAPK
could be part of the acantholytic mechanism of PV IgG and
that blocking p38MAPK activity might have a role in pre-
venting PV IgG-induced blistering. Indeed, we then dem-
onstrated that pharmacological inhibitors of p38MAPK
prevented in vivo blister formation in the PV passive
transfer mouse model.27 Furthermore, phosphorylation of
both p38MAPK and HSP27 has been observed in perile-
sional epidermis of pemphigus patients.28
In PF, IgGs that target dsg1 are pathogenic. The sim-
ilar immunobiology of PF and PV led us to hypothesize
that like PV, PF IgGs might activate intracellular signaling
via p38MAPK and HSP27. Using the passive transfer
mouse model, this study was undertaken to determine if
PF IgG induced activation of p38MAPK and HSP25, the
murine HSP27 homolog, in the skin, and if pharmaco-
logical inhibition of p38MAPK could prevent blister
formation in vivo. The results demonstrate that keratin-
ocyte p38MAPK is activated in response to binding of
pathogenic PF IgG to the skin and that inhibiting
p38MAPK blocks the ability of the pathogenic IgG to
cause end-organ damage, eg, blistering, in the skin.
These observations suggest that targeting the mecha-
nism by which the autoimmune response damages the




Rabbit polyclonal anti-HSP25 antibodies were from
StressGen (Ann Arbor, MI). Rabbit monoclonal anti-phos-
pho HSP27 antibodies, rabbit monoclonal anti-phospho-
p38MAPK (Thr180/Tyr182) antibodies, and horseradish
peroxidase-linked anti-rabbit secondary antibodies were
from Cell Signaling Technologies (Beverly, MA). Rabbit
polyclonal anti-p38MAPK antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA) and polyclonal anti-
lactate dehydrogenase V antibodies were from Cortex
Biochem (San Leandro, CA). Rabbit anti-sheep horserad-
ish peroxidase-conjugated secondary antibodies were
from Cortex Biochem. The p38MAPK inhibitors SB202190
and SB203580, and the inactive analog SB202474 were
from Calbiochem (La Jolla, CA).
IgG Preparation
PF sera were previously described.29,30 Data presented
in Figures 1 to 3 are from IgGs purified from a single PF
patient, PF1, whose serum was available in sufficient
quantities to perform the described studies; the activity of
this serum was determined by indirect immunofluores-
cence on human skin with a titer of 1:160. A second
independent series of experiments (Supplementary Fig-
ure S1, see http://ajp.amjpathol.org) used PF IgGs puri-
fied from sera of a second patient, PF2, (whose activity
was determined by indirect immunofluorescence on hu-
man skin with a titer of 1:80) and showed similar results.
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Both sera were positive by dsg1 enzyme-linked immu-
nosorbent assay (ELISA) and negative by dsg3 ELISA.
PF IgGs were purified from PF patient sera by ammonium
sulfate precipitation followed by affinity chromatography
on Protein G (HiTrap; Pharmacia, Piscataway, NJ) as
previously described.26 IgG fractions were dialyzed
against phosphate-buffered saline (PBS) and sterile-fil-
tered. Purity was confirmed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and ac-
tivity assayed by indirect immunofluorescence and
ELISA. Control IgGs (no activity by indirect immunoflu-
orescence) were prepared in parallel from normal hu-
man sera.
Passive Transfer Mouse Model
Breeding pairs of C57BL/6J mice were purchased from
The Jackson Laboratory (Bar Harbor, ME) and main-
tained at the University of North Carolina DLAM Facility in
accordance with Institutional Animal Care and Use Com-
mittee protocols. Neonatal mice (24 to 36 hours old with
body weights between 1.4 g and 1.6 g) were used for
passive transfer experiments. Neonates were injected
intradermally with a sterile solution of either control IgGs
or PF IgGs as described previously.4,31,32 For direct clin-
ical examination, mice (n  3) were injected with PF IgGs
(PF1: 0.10 mg IgG/g animal weight) in a total volume of 50
l of PBS. This dose of PF IgGs resulted in gross slough-
ing of the skin. Alternatively, mice (n  3) were prein-
jected with 18.75 g of SB203580 in 50 l intradermally
then at 2 hours re-injected intradermally with 18.75 g of
SB203580  PF IgG/50 l (total of 37.5 g of SB203580).
The skin of neonatal mice from PF IgG and PF IgG 
inhibitor-treated groups was examined 18 hours after the
injection of IgG for the presence of Nikolsky’s sign, in
which gentle friction of perilesional skin causes sheet-like
sloughing of the epidermis.
A second group of animals (n  3 mice) received a
lower dose of PF IgGs (PF1, 0.015 mg/g body weight in
50 l of PBS) to preserve the cutaneous architecture lost
by epithelial sloughing at the higher dose. After clinical
examination, the animals were sacrificed, and skin and
serum specimens obtained for routine histological exam-
ination using light microscopy (hematoxylin and eosin
staining) and direct immunofluorescence assays to de-
tect keratinocyte cell surface-bound pemphigus IgGs.
Serum samples were assayed for the presence of circu-
lating human anti-dsg1 IgGs by ELISA against baculovi-
rus expressed ectodomains of human dsg1 as previously
described.33 Additional skin samples were harvested to
prepare protein extracts for SDS-PAGE and two-dimen-
sional gel electrophoresis. After transfer to polyvinylidene
difluoride, membranes were probed by immunoblot for
proteins of interest. For in vivo inhibitor studies, mice (n 
3 mice per treatment group) were preinjected with 6.25
g of SB202190 in 50 l intradermally then at 2 hours
re-injected intradermally with 6.25 g of SB202190  PF
IgG/50 l (total of 12.5 g of SB202190). No increased
mortality was observed in the inhibitor versus control
mice. As a control, a separate group of mice (n  3) were
pretreated with the inactive analog SB202474 (total of
12.5 g of SB202470)34 following the split dose protocol
used for SB202190. Additionally, a third group of mice
(n  3) were pretreated with the p38MAPK inhibitor
SB203580 (total of 25 g of SB203580) following the split
dose protocol used for SB202190. Typically, neonatal
litters were groups of five to six mice. Because of the
large numbers of mice used for this study, not all mice
were injected at the same time, but rather, based on
availability of neonatal litters.
Two-Dimensional Gel Electrophoresis
Extracts were prepared from skin biopsies by Dounce
homogenization in IEF lysis buffer (8 mol/L urea, 4%
CHAPS, 2.5 mmol/L dithiothreitol, 40 mmol/L Tris, 10
mol/L pepstatin, 100 mol/L leupeptin, 10 mol/L E-64,
1 mmol/L phenylmethyl sulfonyl fluoride). Protein concen-
tration was by modified Bradford as described.35 IPG
buffer (pH 4 to 7, Pharmacia) was added to each sample
to a final concentration of 0.5% before isoelectric focus-
ing. Samples were separated in the first dimension using
7-cm, pH 4 to 7, linear IPGphor strips (Pharmacia) and in
the second dimension by 10% SDS-PAGE. Gels were
transferred to polyvinylidene difluoride membranes for
immunoblot analysis. Western blots were developed by
enhanced chemiluminescence (ECL) reaction and the
signal intensity quantified by scanning chemilumines-
cence on a GeneGnome scanner (Syngene Bio Imag-
ing, Frederick, MD) using GeneSnap software. The
signal intensity for each HSP25 isoform was expressed
as a percentage of total HSP25 using the formula Pn/
(P0  P1  P2), where, n corresponds to the signal
intensity for spot 0, 1, or 2, and P0  P1  P2 is the
summed signal intensity for all three HSP25 isoforms.
Statistical significance was determined using the Stu-
dent’s t-test.
Results
Neonatal C57BL/6J mice were injected intradermally
with PF IgGs purified from PF patient sera or control
IgG from nonaffected individuals. After 18 hours, mice
were examined clinically for the presence of blister
formation. Additionally, skin biopsies were obtained for
histological examination, immunohistochemical staining,
and for biochemical analyses. Pretreatment by intrader-
mal injection of the p38MAPK inhibitors SB203580,
SB202190, or the inactive analog SB202474, followed by
passive transfer of PF IgGs was used to determine
whether inhibition of p38MAPK blocked PF IgG-mediated
acantholysis in vivo.
Phosphorylation of p38MAPK and HSP25 Was
Observed in Skin of PF IgG-Treated Mice
Extracts from biopsies were prepared by tissue ho-
mogenization in IEF lysis buffer and separated by SDS-
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PAGE and two-dimensional gel electrophoresis. After
electrotransfer, polyvinylidene difluoride membranes
were probed with antibodies to p38MAPK, phospho-
p38MAPK, and HSP25. Compared to control IgG-treated
mice, increased levels of phospho-p38MAPK were de-
tected in skin biopsies from PF IgG-treated mice. The
increase in phosphorylation was approximately twofold
greater than baseline levels in controls. PF IgG-induced
phosphorylation of p38MAPK was blocked when mice
were pretreated with the p38MAPK inhibitors SB203580
(Figure 1, A and B) or SB202190 (data not shown), but
not in mice pretreated with the inactive analog SB202474.
In skin biopsies from PF IgG-treated mice, the blister
roof and floor could be readily separated from one
another and independently analyzed. As seen in Figure
1, phopsho-p38MAPK was found predominantly in the
blister roof.
Phosphorylation of HSP25 occurs as a downstream
consequence of p38MAPK-mediated kinase activity.
Predicting that PF IgG-induced phosphorylation of
p38MAPK would result in phosphorylation of HSP25,
we next examined the phosphorylation state of HSP25
in PF IgG-treated mice. When skin extracts were sep-
arated by two-dimensional gel electrophoresis, three
HSP25 charge isoforms were detected, P0, P1, and P2;
P0 is nonphosphorylated HSP25; whereas, P1 and P2
represent phosphorylated isoforms of HSP25.26,27 In-
creased amounts of the most negatively charged P2
isoform were detected in skin of PF IgG-treated mice
compared to controls. Additionally, PF IgG-induced
phosphorylation of HSP25 was diminished in mice pre-
treated with either of two p38 inhibitors SB203580 (Fig-
ure 1, C and D) or SB202190 (data not shown), but not
the inactive analog SB202474.
Inhibitors of p38MAPK Block PF IgG-Induced
Blister Formation
Mice treated with PF IgGs were Nikolsky-positive, ex-
hibiting gross blister formation. Importantly, inhibition
of p38MAPK prevented the ability of PF IgGs to induce
blister formation (Figure 2, Table 1). Similarly, routine
histological examination of PF IgG-treated mice dem-
onstrated acantholysis; however, PF IgG-induced ac-
antholysis was prevented in mice pretreated with the
p38MAPK inhibitor SB203590 (Figure 2, Table 2) or
SB202190 (data not shown), but not the inactive analog
SB202474.
Figure 1. Increased phosphorylation of p38MAPK in the skin of PF IgG-
treated mice. Neonatal C57BL/6 wild-type mice were injected intradermally
with control IgG (CON, 0.015 mg of IgG/g body weight), PF IgG (0.015 mg
of IgG/g body weight), SB203580 and then PF IgG (PF IgG  SB203580), or
the inactive analog SB202474 and then PF IgG (PF IgG  SB202474). Skin
biopsies were obtained after 18 hours of treatment and extracted in IEF lysis
buffer. A: Samples were equally loaded, separated by 10% SDS-PAGE, trans-
ferred to polyvinylidene difluoride, and immunoblotted with antibodies to
p38MAPK, phospho-p38MAPK (phospho-p38), or total p38MAPK (p38).
Blots were developed by ECL reaction (Amersham Pharmacia). Band inten-
sities of phospho-p38MAPK were normalized to the band intensities of total
p38MAPK. Extracts prepared from the blister roof and floor of skin biopsies
of PF IgG were similarly analyzed. A: Representative Western blot. B: Signal
intensity from the ECL reaction for each band was quantified with a GeneG-
nome scanner (Syngene Bio Imaging) by using GeneSnap software (n  3
mice per treatment condition; SD shown by error bars). P values are as
follows: i) PF IgG compared to control, P  0.002; ii) PF IgG  SB203580
compared to PF IgG, P  0.004; iii) PF IgG  SB202474 compared to PF IgG,
P  0.181; iv) blister roof compared to blister floor, P  0.03. P values were
calculated by using the Student’s t-test. Increased phosphorylation of HSP25
in the skin of PF IgG-treated mice. Increased amounts of the most negatively
charged HSP25 isoform (P2) were observed in PF IgG-treated mice and
blocked in mice pretreated with SB203580, but not with the inactive analog
SB202474. Neonatal C57BL/6 wild-type mice were injected intradermally
with control IgG (CON, 0.015 mg of IgG/g body weight), PF IgG (0.015 mg
of IgG/g body weight), SB203580 and then PF IgG (PF IgG  SB203580), or
SB202474 and then PF IgG (PF IgG  SB202474). Skin biopsies were ob-
tained after 18 hours of treatment and extracted in IEF lysis buffer. C: Skin
extracts (30 g) were prepared and separated in the first dimension by using
7 cm, pH 4 to 7, IPGphor strips (Amersham Pharmacia Biosciences) and in
the second dimension by 10% SDS-PAGE, followed by immunoblotting with
antibodies to murine HSP25 as described. Blots were developed by ECL
reaction (Amersham Pharmacia). C: Representative Western blots of
region of the two-dimensional gels showing HSP25 charge isoforms. D:
Signal intensity from the ECL reaction for each spot corresponding to the
two-dimensional gel HSP25 charge isoforms labeled P0, P1, and P2 were
quantified as above with a GeneGnome scanner and GeneSnap software
(n  3 mice per treatment condition, SD shown by error bars). Values
were expressed as a percentage of total HSP25 by using the formula
Pn/(P0  P1  P2), where Pn corresponds to the signal intensity for n 
spot 0, 1, or 2 and P0  P1  P2 is the summed signal intensity for all
three HSP25 isoforms. An increase in the percentage of the most
negatively charged HSP25 isoform, P2, is observed in skin extracts from PF
IgG versus control-treated mice (P  0.01). This increase is blocked in
mice pretreated with SB203580 (P  0.001 compared with PF IgG-treated
mice), but not the inactive analog SB202474 (P  0.4 compared with PF
IgG-treated mice). P values were calculated by using the Student’s t-test.
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p38MAPK Inhibitors Do Not Block Systemic
Absorption or Keratinocyte Binding of PF IgG
When assayed by ELISA against the recombinant dsg1
ectodomain, both PF IgG-treated and PF IgG  inhibitor-
treated mice had similar levels of circulating human anti-
dsg1 IgG (Figure 3A). Thus, the p38MAPK inhibitors did
not prevent systemic absorption of the intradermally
delivered autoantibodies. As expected, direct immuno-
fluorescence of skin biopsies of PF IgG-treated mice
demonstrated anti-human IgGs bound to the epidermal
keratinocyte cell surface (Figure 3, B and C). Importantly,
epidermal binding of PF IgGs was not blocked by pre-
treatment with SB203580 (Figure 3D), SB202190 (data
not shown), or SB202474 (Figure 3E). These observations
indicate that the p38MAPK inhibitors act downstream of
antibody binding to the target keratinocytes consistent
with the proposed role for p38MAPK and HSP25 in the
mechanism of acantholysis.
A Second PF IgG Activates Signaling via p38
MAPK and HSP25
To exclude the possibility that the observed signaling
events were unique to the particular PF IgG used in the
above experiments, we examined the ability of a PF IgG
purified from a second patient sera to activate signaling
in vivo. Similar to the results observed with purified PF1
IgG, mice injected with purified PF2 IgG demonstrated
acantholysis (Supplementary Figure S1A, see http://ajp.
amjpathol.org), and increased phosphorylation of both
p38MAPK and HSP25 compared to controls (Supple-
mentary Figure S1, C–E, see http://ajp.amjpathol.org). In-
hibitors of p38MAPK blocked the ability of PF IgG to
induce both p38MAPK and HSP25 phosphorylation and
blister formation (Supplementary Figure S1, B–E, see
http://ajp.amjpathol.org) in the skin of test animals.
Discussion
In PF, autoantibodies directed against the human des-
mosomal cadherin dsg1 induce blistering. We used an in
vivo model to investigate the hypothesis that PF IgGs
activate signaling in target keratinocytes and that these
signaling events are part of the mechanism by which
autoantibodies induce acantholysis. Using the passive
transfer mouse model of PF, increased phosphorylation
of the MAP kinase p38 was observed in skin biopsies of
PF IgG-treated mice.
In contrast to suprabasilar acantholysis observed in
PV, pathogenic PF IgGs induce blistering in the more
superficial spinous and granular layers of the epidermis.
Separation of the blister roof and floor from skin of PF
IgG-treated mice and subsequent analyses by immuno-
blot demonstrated that the increased phospho-p38MAPK
signal was localized to the blister roof, indicating that the
epidermal keratinocytes were the source of the increased
phospho-p38MAPK signal.
Figure 2. Inhibiting p38MAPK prevents clinical blistering in PF passive
transfer mice. Neonatal C57BL/6J mice were injected intradermally with
either PF IgG (0.1 mg of IgG/g body weight) (A) or PF IgG (0.1 mg of IgG/g
body weight) plus SB2023580 (B). After 18 hours, the skin of neonatal mice
from the test and control groups was examined clinically. PF IgG-treated
mice have a positive Nikolsky’s sign (white arrows), demonstrating loss of
epithelial cell-cell adhesion. In contrast, mice treated with the SB203580 and
PF IgG have a negative Nikolsky’s sign, indicating that epithelial adhesion
remains intact. Inhibiting p38MAPK prevents histological blistering in PF
passive transfer mice. Representative skin biopsies of mice treated with
control IgG (0.015 mg of IgG/g body weight) (C), PF IgG (0.015 mg of IgG/g
body weight) (D), SB203580 and then PF IgG (E), and SB202474 and then PF
IgG (F), were fixed in formalin and stained with H&E. Acantholysis leading
to blister formation is seen in PF IgG-treated mice, but is blocked in mice
treated with the p38MAPK inhibitor SB203580, but not the inactive analog
SB202474.





PF1 IgG 3 0
PF1 IgG  SB203580 0 3
Neonatal mice were injected with PF IgG (0.1 mg/g) or PF IgG plus
SB203580 and examined 18 hours later for Nikolsky’s sign.





Control IgG 0 3
PF1 IgG 3 0
PF1 IgG  SB203580 0 3
PF1 IgG  SB202474 3 0
Neonatal mice were injected with control IgG (0.015 mg/g), PF IgG
(0.015 mg/g), or PF IgG and either the active p38 inhibitor SB203580 or
the inactive analog SB202474. Mice were examined 18 hours later for
the presence of blister formation by light microscopy of H&E-stained
skin biopsy sections.
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One of the downstream targets for p38MAPK, via
MAPKAP2 (MK2), is HSP27 (or the murine homolog,
HSP25).35–37 Consistent with the activation of p38MAPK
by PF IgG, increases in the amount of the most negatively
charged HSP25 isoform were also observed in skin of PF
IgG-treated mice. As previously shown,25,26 this most
negatively charged isoform corresponds to phosphory-
lated HSP25. Furthermore, increased phospho-HSP25
immunoreactivity was detected on Western blots of
skin extracts from PF IgG-treated mice compared to
controls (Supplementary Figure S1, C and E, see
http://ajp.amjpathol.org).
Use of either of the two p38MAPK inhibitors SB203580
or SB202190 inhibited the PF IgG-induced phosphoryla-
tion of both p38MAPK and HSP25; the structurally related
but inactive analog SB202474 failed to block these PF
IgG-induced phosphorylation events. Importantly, inhibi-
tion of p38MAPK activity blocked the ability of PF IgG to
cause blister formation in the passive transfer mouse
model. Inhibition of p38MAPK did not prevent systemic
absorption of the PF IgGs nor the ability of the PF IgGs to
diffuse and bind the epidermal keratinocytes indicating
that the inhibitors blocked blister formation by inhibiting
the ability of the bound antibody to activate signaling
across the keratinocyte cell membrane. These observa-
tions suggest that similar to the related disease PV, PF
IgGs activate intracellular signaling and that these sig-
naling events are part of the mechanism by which patho-
genic PF autoantibodies induce acantholysis. PF IgGs
purified from a second PF patient serum demonstrated
similar results.
Acantholysis represents a biological transition from a
state of cell-cell adhesion to loss of adhesion, sharing
some of the morphological and likely biological changes
associated with the transition from a stationary to a motile
cell. Consistent with this hypothesis is the observation
that pemphigus IgG induces changes to both the inter-
mediate filament and actin cytoskeleton.25 For example,
the actin cytoskeleton transitions from a cortical staining
pattern to one reminiscent of a migrating cell in primary
human keratinocytes incubated with purified pemphigus
IgG. Importantly, this pemphigus IgG-induced shift in the
both the actin and intermediate filament cytoskeletons is
p38MAPK-dependent because both cytoskeletal transi-
tions were blocked when pemphigus IgG-incubated cells
were first treated with SB202190 or SB203580, two small
molecular weight inhibitors of p38MAPK.25
A signaling complex is formed by p38MAPK, MAP
kinase-activated protein kinase 2 (MAPKAP2, MK2), and
HSP27; activation of p38MAPK, with subsequent phos-
phorylation of MK2 and then HSP27, releases phosphor-
ylated HSP27 from this complex.38 In retrospect, the role
of the p38MAPK-MK2-HSP27 signaling cassette in pem-
phigus acantholysis should not be surprising. The
p38MAPK-MK2-HSP27 signaling cassette has been
shown to regulate the cytoskeleton. HSP27 itself regu-
lates actin and intermediate filament organization.39 Ad-
ditionally, HSP27 functions as an actin-capping protein.40
p38MAPK-MK2-dependent phosphorylation of HSP27 re-
leases HSP27 mediated inhibition of actin polymeriza-
tion41,42 and promotes cell migration.43–45 Similarly,
p38MAPK and HSP27 also regulate the intermediate fil-
ament cytoskeleton. For example, a role for HSP27 in
intermediate filament regulation is suggested by the ob-
servation that HSP27 missense mutations disrupt neuro-
filament assembly, leading to the neuromuscular disorder
Figure 3. The inhibitors do not prevent systemic absorption of the injected IgG: anti-dsg1 IgG serum levels. Serum samples obtained from control IgG, PF
IgG-treated, PF IgG plus SB203580-treated, and PF IgG plus SB202470-treated mice were examined for the presence of anti-dsg1 autoantibodies by using a dsg1
ectodomain-based ELISA. (A) No significant differences in circulating anti-dsg1 IgG were found in mice pretreated with the active p38MAPK inhibitor or the
inactive analog when compared to mice treated with PF IgG alone. P values are as follows: i) PF IgG compared to control, P  0.004; ii) PF IgG  SB203580
compared to PF IgG, P  0.27; iii) PF IgG  SB202474 compared to PF IgG, P  0.4. SD is shown by error bars (n  3 mice per treatment group); P values were
calculated by using the Student’s t-test. The inhibitors do not prevent the diffusion of IgG to the epidermis. Perilesional skin biopsies from control IgG (B), PF
IgG-treated (C), PF IgG plus SB203580-treated (D), and PF IgG plus SB202470-treated (E) mice were examined for the presence of human anti-dsg1 PF IgG by
direct immunofluorescence by using a mouse anti-human Cy-2-conjugated monoclonal antibody. A honeycomb pattern of staining in the epidermis is seen in mice
treated with PF IgG, PF IgG plus SB203580, and PF IgG plus SB202474, demonstrating that the inhibitors do notprevent binding of PF autoantibodies to the
keratinocyte cell surface.
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Charcot-Marie-Tooth disease and to distal hereditary mo-
tor neuropathy.47 Keratin intermediate filament phosphor-
ylation is p38MAPK-dependent48,49 and keratin filament
organization is regulated by p38MAPK phosphoryla-
tion.49,50 For example, phosphorylation of the basal cell
layer keratin 5 by p38MAPK is associated with increased
keratin solubility and keratin filament collapse.50
In addition to its ability to regulate the actin cytoskele-
ton through its effects on HSP27 phosphorylation,51–53
direct regulation of the keratin intermediate filament cy-
toskeleton by p38MAPK may be relevant to acantholysis.
For example, phosphorylation of keratin 8 (K8) and K19 in
glandular epithelia has been shown to be p38MAPK-
dependent and to increase keratin solubility.48 Interest-
ingly, Reichelt and colleagues54 reported that loss of
keratin 10 leads to activation of p38MAPK in keratino-
cytes in the K10 knockout mouse model. Further biolog-
ical links between keratins and p38MAPK were shown in
a recent study in which orthovanadate-induced keratin
filament network disassembly was monitored by live-cell
fluorescence microscopy. Orthovanadate-induced kera-
tin granules were observed to co-localize with p38MAPK.
Furthermore, up-regulation of p38MAPK activity induced
keratin granule formation, whereas down-regulation blocked
disassembly of keratin filament networks.55
The role of p38MAPK and intracellular signaling in PV
IgG-induced acantholysis has been recently confirmed
by other investigators.23,56,57 Data from Washke and col-
leagues56 suggests a role for Rho GTPases in pemphi-
gus acantholysis. Using an ex vivo human skin model and
cultured HaCaT cells, they demonstrated that the Rho A
activator cytotoxic necrotizing factor-y blocked pemphi-
gus IgG-induced skin splitting. Incubation of cultured
cells with PV or PF IgGs reduced the activity of Rho A to
50% of control levels. Moreover, activation of Rho A by
cytotoxic necrotizing factor-1 was reduced in the pres-
ence of pemphigus IgG. Interestingly, the p38MAPK
inhibitor SB202190 not only inhibited PV IgG-triggered
keratinocyte dissociation, but also abolished PV IgG-
triggered Rho A inactivation.56 Their results provide ad-
ditional data to support a role for p38MAPK in pemphigus
acantholysis and further suggest that Rho A may be one
of the downstream targets for p38MAPK in this signaling
cascade. It is worth noting that in other disorders,
activation of p38MAPK in keratinocytes is observed in
the absence of blistering. For example, activation of
p38MAPK to approximately fourfold greater than baseline
has been observed in lesional psoriatic keratinocytes58;
however, acantholysis is not a feature of psoriasis. Thus,
the role of p38MAPK activation and its relationship to
changes in adhesion are likely to be context-dependent.
One possibility is that different subcellular pools of
p38MAPK are present in keratinocytes and that the sub-
cellular location of p38MAPK, as well as its association
with other cellular proteins, dictates its function.
Although the above data indicate a role for intracellular
signaling in the mechanism of pemphigus acantholysis,
the precise mechanism by which this signal is initiated
has yet to be elucidated. PF IgGs, as well as PV IgGs,
likely initiate signaling by acting as competitive inhibitors
of the dsg adhesive interactions across the desmosome
interface (Figure 4). Structural analysis of dsg cadherin
interactions, including mapping of the polypeptide back-
bone of dsg extracellular domains/ectodomains to the
crystal structure of E-cadherin as well as EM-tomograms
of desmosomes indicate that the N-terminal EC1 domains
are the site of desmosomal cadherin-adhesive interac-
tions.59,60 Importantly, both pathogenic monoclonal IgG
and IgG from patient sera bind to the EC1/2 epitopes
within the N-terminus of dsg; whereas, nonpathogenic
IgG and monoclonal antibodies bind to other regions of
the dsg ectodomain. Thus, antibody binding to the dsg
N-termini may compete for desmosomal cadherin adhe-
sive interactions, either in cis- or trans. The binding of
autoantibodies to dsg1 may initiate signaling by compet-
ing for binding to the region of the dsg ectodomain that
forms the adhesive interface. This concept is supported
by the observation that monovalent PV and PF IgG
Fab19,29 and anti-dsg single-chain variable region frag-
ments (ScFvs),61 which are incapable of crosslinking
desmosome cadherins, induce loss of adhesion.
The studies of the mechanism by which pemphigus
autoantibodies lead to end-organ damage in the skin are
beginning to define a series of biochemical events that
lead to a coordinated cellular response that results in the
decreased adhesion and subsequent blister formation in
PV and PF. Our observations suggest that targeting spe-
cific components of this pathway can be used as a ther-
apeutic strategy to treat autoimmune blistering diseases.
Current treatments for pemphigus autoimmune diseases
are directed at decreasing the autoimmune response,
Figure 4. Model of mechanism of pemphigus acantholysis. Pathogenic PF
IgG may initiate signaling by acting as competitive inhibitors for trans and/or
cis-interactions within the EC1/2 region of the desmosome cadherin dsg1 at
the desmosome adhesive interface. The signal is likely propagated by mod-
ulation of a docking plexus on the cytoplasmic surface of the membrane and
may include the cytoplasmic tail of dgs1 as well as associated proteins such
as plakoglobin, desmoplakin, and plakophilin. Activation of p38MAPK and
HSP25/27 contributes to reorganization of keratin intermediate filaments and
the actin cytoskeleton with subsequent loss of keratinocyte cell-cell adhesion
and clinical blister formation in the superficial layers of the epidermis. DSC,
desmocollin; DSG, desmoglein; DP, desmoplakin; KIF, keratin intermediate
filament; PG, plakoglobin; PKP, plakophilin.
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often in a nonspecific manner. In contrast, the observa-
tions presented in this study suggest an alternative ap-
proach to treating autoimmune disease that does not
require immunosuppression. Rather, specific therapies
targeted at key molecules that are part of the mechanism
by which the autoimmune response mediates end-organ
damage may represent an alternative approach to treat-
ing autoimmune disease without the need for broad im-
munosuppressive medications.
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